Samarth Kulkarni, Ph.D

Samarth Kulkarni, Ph.D

Chair of the BoardatCRISPR Therapeutics AG· In proxies 2021–2025

Pay in FY2025-77% from the year before · CRISPR Therapeutics AG stock +33.2% the same year

Samarth Kulkarni, Ph.D was paid $7.7M in FY2025 (Dec), down 77%. CRISPR Therapeutics AG stock rose 33.2% that year.

Pay$100 in the stock at the end of FY20 → $34
Pay is from the Summary Compensation Table of each CRISPR Therapeutics AG proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Oruka TherapeuticsPublic company · 2 yr
    • Chair of the Board2024 – Present · 2 yrNo stock prices for these years
  2. Black Diamond TherapeuticsPublic company · 3 yr
    • Lead Independent Director2023 – Present · 3 yrNo stock prices for these years
  3. CRISPR Therapeutics AGPublic company · 5 yr
    • Chairman and Chief Executive Officer2021 – Present · 5 yrStock in role -68%
  4. Centessa PharmaceuticalsPublic company · 5 yr
    • Director2021 – Present · 5 yrNo stock prices for these years
  5. Black Diamond Therapeutics, Inc.Public company · 6 yr
    • Director2020 – Present · 6 yrNo stock prices for these years
  6. Repare Therapeutics Inc.Public company · 7 yr
    • Director2019 – Present · 7 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Black Diamond TherapeuticsLead independent director · 6 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?